Latest News

Newly published longitudinal fMRI data revealed that presymptom Huntington gene carriers had striatal network shifts up to 20 years early, potentially sharpening targets for studies in the future.

The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.

A recently published multiple sclerosis study suggests disease-modifying therapy use may be associated with higher rates of human papillomavirus positivity, cervical abnormalities, and other gynecologic complications.

Thayne Munce, PhD, discusses the challenges and unanswered questions shaping CTE research, as well as the implications of findings from former NFL players for athletes competing today.

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

The randomized NATURE trial, presented as late-breaking science at ESC Congress 2026, showed that enVast-assisted thrombectomy reduced infarct size versus standard PCI in STEMI with large thrombus burden.

The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Findings showed that remibrutinib outperformed teriflunomide in the REMODEL-1 and REMODEL-2 phase 3 trials among adults with relapsing MS, lowering relapse rates and MRI lesions with a favorable safety profile.

Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.